Cantel Medical Completes Acquisition of Endoscopy Assets from CR Kennedy in Australia

CANTEL MEDICAL CORP. announced the completion of its acquisition of endoscopy business assets from Australian distributor, CR Kennedy & Company Pty. Ltd.
The endoscopy business assets consist of Cantel’s Medivators®-branded automated endoscope reprocessors, chemistries, procedure room products as well as a full sales and service organization. The incremental revenue of the assets being acquired is approximately $8 million on an annualized basis.
“We’re excited to complete the acquisition with CR Kennedy. The successful completion of this transaction further strengthens our commitment to provide infection prevention products and solutions globally,” stated David Rosen, President, Continental Europe, Middle East and Asia-Pacific. “We would like to thank CR Kennedy for their partnership and the role they played in helping us achieve this milestone. Also, we welcome our new colleagues to the Cantel family.”
About Cantel Medical
Cantel Medical is a leading global company dedicated to delivering innovative infection prevention products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives.  Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products. Additionally, we provide technical service for our products.  For further information, visit the Cantel website at www.cantelmedical.com .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel’s filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.